Drug intelligence / Profile preview

LP-A18

Development stage: Discontinued
Lead developer: Lantern Pharma

Overview

LP-A18 is a discontinued preclinical or early research-stage anticancer drug candidate from Lantern Pharma. Publicly available information identifies it only as a neoplasm-focused development program and does not clearly disclose the active ingredient, molecular target, mechanism of action, modality, formulation, route of administration, or any commercial brand name. Based on the available evidence, LP-A18 appears to have been an internal oncology asset that was not advanced and is no longer in active development.

Beyond the preview

Go deeper on LP-A18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-A18.

Explore the full profile